Yuji Shimamoto

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

Tetsuhiko Shirasaka, Yuji Shimamoto, Masakazu Fukushima · PubMed · 1993 · 350 citations

Antitumor Activity, Gastrointestinal Pharmacology, Pathology +19

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

Tetsuhiko Shirasaka, Yuji Shimamoto, Hideyuki Ohshimo et al. · Cancer Chemotherapy and Pharmacology · 1993 · 152 citations

Oncology, Medicine, Pharmacology +11

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

M Fukushima, Hirofumi Satake, Junji Uchida et al. · International Journal of Oncology · 1998 · 105 citations

Tumor Biology, Tumor Xenografts, Oncology +14

Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3- C -ethynyl-β- D - ribo -pentofuranosyl)cytosine and 1-(3- C -ethynyl-β- D - ribo -pentofuranosyl)uracil

Satoshi Takatori, Hiroshi Kanda, Kiyoko Takenaka et al. · Cancer Chemotherapy and Pharmacology · 1999 · 60 citations

Ribo -Pentofuranosyl, Medicinal Chemistry, Medicine +6

Sensitivity of Human Cancer Cells to the New Anticancer <i>Ribo</i>‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2

Yuji Shimamoto, Katsuhisa Koizumi, Hiroyuki Okabe et al. · Japanese Journal of Cancer Research · 2002 · 54 citations · Full text

Uridine‐cytidine Kinase 2, Cancer Biology, Tumor Biology +20